Stimulant medications are the first-line pharmacological treatment for ADHD — but they’re not right for everyone. Whether you have significant anxiety, a history of substance use, a cardiovascular condition, or simply find that stimulants don’t agree with you, there are evidence-based non-stimulant options that can effectively manage ADHD symptoms. Dr. Mark G. Agresti offers comprehensive ADHD evaluation and individualized treatment in Palm Beach and via telehealth throughout Florida, including the full range of non-stimulant medication options.
Why Consider Non-Stimulant Options?
Stimulants are effective for approximately 70–80% of adults with ADHD, but there are important reasons a non-stimulant approach may be preferred or necessary:
- Co-occurring anxiety: Stimulants can worsen anxiety in some individuals. When both ADHD and anxiety are significant, a non-stimulant or combination approach may produce better overall outcomes.
- Substance use history: Stimulants are Schedule II controlled substances. Patients with active or recent substance use disorders are often better served by non-controlled medications.
- Cardiovascular concerns: Some patients have cardiac risk factors — arrhythmias, elevated blood pressure, structural abnormalities — that make stimulants inadvisable or require very careful monitoring.
- Stimulant side effects: Intolerable appetite suppression, insomnia, anxiety, or cardiovascular effects may make non-stimulant options much more tolerable for some patients.
- Stimulant rebound: The wear-off effects of stimulants — irritability, emotional lability, rebound inattention in the evening — can be disruptive enough that a non-stimulant’s steady-state profile is preferable.
- Personal or professional preference: Some patients prefer not to take controlled substances for lifestyle reasons, certain security clearances, or professional certifications.
Strattera (Atomoxetine)
Strattera (atomoxetine) was the first non-stimulant specifically FDA-approved for ADHD, and it remains the most studied medication in this class. It is not a controlled substance and carries no known abuse potential.
Atomoxetine works as a selective norepinephrine reuptake inhibitor (SNRI) — blocking norepinephrine reuptake in the prefrontal cortex and improving attention and executive function through a different pathway than stimulants. Its weaker dopamine effect partly explains its lower abuse potential and somewhat different efficacy profile.
- Takes 4–8 weeks to reach full therapeutic effect — patience is required
- Provides steady, 24-hour coverage without peaks and valleys
- No “wearing off” effect; no rebound irritability
- May benefit patients with comorbid anxiety
- Not subject to controlled-substance prescribing restrictions or supply shortages
- Common side effects: dry mouth, decreased appetite, nausea (especially early), fatigue, mood changes
Strattera is FDA-approved for ADHD in adults and is available as generic atomoxetine.
Wellbutrin (Bupropion)
Wellbutrin (bupropion) is primarily known as an antidepressant, but it has meaningful clinical evidence supporting off-label use for adult ADHD — particularly when ADHD and depression or depressive symptoms co-occur. It is not FDA-approved for ADHD specifically, but is widely prescribed for this purpose and supported by the clinical literature.
Bupropion works as a norepinephrine-dopamine reuptake inhibitor (NDRI), increasing dopamine and norepinephrine signaling in the prefrontal cortex without being a stimulant or a controlled substance.
Wellbutrin may be a good fit when:
- ADHD co-occurs with depression — one medication addresses both
- The patient also smokes or is trying to quit (bupropion has an FDA-approved smoking cessation indication as Zyban)
- A once-daily non-stimulant is preferred
- Controlled-substance prescribing is not appropriate
Wellbutrin XL is taken once daily. It carries a small, dose-dependent increased seizure risk — an important consideration for patients with seizure history.
Intuniv (Guanfacine)
Intuniv is the extended-release formulation of guanfacine — an alpha-2A adrenergic receptor agonist originally developed as an antihypertensive. Guanfacine improves attention and reduces hyperactivity and impulsivity by acting on receptors in the prefrontal cortex through a mechanism entirely distinct from stimulants or Strattera.
Intuniv is FDA-approved for ADHD in children and adolescents and is commonly used off-label in adults. It is not a controlled substance and has a particularly favorable profile for:
- Prominent hyperactivity and impulsivity symptoms
- Emotional dysregulation associated with ADHD
- Patients with significant anxiety (guanfacine has calming properties)
- Combination use: adding Intuniv to a stimulant can address residual hyperactivity and allow a lower stimulant dose
- Patients with tic disorders or Tourette syndrome combined with ADHD
Common side effects include sedation (especially early in treatment), low blood pressure, and dizziness — these typically improve with dose adjustment over time. Intuniv should be tapered rather than stopped abruptly.
Qelbree (Viloxazine)
Qelbree (viloxazine extended release) is the newest FDA-approved medication specifically for ADHD and brings a novel mechanism to the non-stimulant category. Originally used as an antidepressant in Europe, viloxazine was reformulated and received FDA approval for ADHD in children and adolescents in 2021, with adult approval following.
Viloxazine works primarily as a selective norepinephrine reuptake inhibitor with additional serotonergic activity — a distinct pharmacological profile from atomoxetine. Patients who haven’t responded to Strattera may respond differently to Qelbree because of these differences.
- Not a controlled substance — no DEA restrictions, no abuse potential
- Once-daily dosing (capsule can be opened and sprinkled on food)
- Effects may emerge within 1–2 weeks — somewhat faster than Strattera
- FDA-approved specifically for ADHD (not off-label)
- Common side effects: somnolence, decreased appetite, nausea, insomnia
- Note: viloxazine inhibits CYP1A2 enzymes — drug interactions worth reviewing
Combining Approaches
Non-stimulant and stimulant medications are not mutually exclusive. A combination approach can sometimes achieve better overall control with fewer side effects than either alone:
- Stimulant + Intuniv/Kapvay: Adding guanfacine or clonidine addresses emotional dysregulation and residual hyperactivity while permitting a lower stimulant dose
- Stimulant + Strattera: Used in cases of partial stimulant response
- Non-stimulant + behavioral strategies: For patients seeking minimal medication, combining a non-stimulant with ADHD coaching or cognitive-behavioral therapy can produce meaningful functional improvements
Personalized Treatment with Dr. Agresti
There is no single best ADHD medication — only the best medication for you, given your full clinical picture. Dr. Agresti brings more than 30 years of psychiatric experience to the evaluation and treatment of adult ADHD. His concierge model means you’re not left navigating side effects alone or waiting weeks for an adjustment. You have direct cell access, same-day refill capability, and a psychiatrist who responds.
Dr. Mark G. Agresti, M.D.
Board-Certified Psychiatrist | 30+ Years Experience
44 Cocoanut Row, Suite M-202, Palm Beach, FL 33480
Call or text to schedule: 561-760-4107
After-hours / emergency: 561-386-7743
Telehealth available for all Florida residents.
Related: ADHD Treatment in Palm Beach | Adderall Treatment | Concierge Psychiatry